MDMA
MDMA, a stimulant. Reverses SERT, DAT, NET to cause non-exocytotic release of serotonin (principal), dopamine, noradrenaline. Also triggers… Oral half-life 8 h.
Reverses SERT, DAT, NET to cause non-exocytotic release of serotonin (principal), dopamine, noradrenaline. Also triggers oxytocin release. Subjective 'entactogenic' state (connection, empathy, emotional openness) distinct from classical psychedelics (5-HT2A agonism minor vs LSD/psilocybin). MAPS Phase 3 trials demonstrated strong PTSD efficacy; FDA rejected 2024 citing trial design concerns (second submission pending).
ABSORPTION-RATE PROVENANCE: this value was derived by inverting the one-compartment peak-time relation in 2026-05-26-wave25-ka-from-tmax.ts, whose header claimed every peak time was verbatim from a primary human study. ALL FORTY-FOUR ENTRIES HAVE NOW BEEN CHECKED AND TWENTY-EIGHT FAIL. This one fails because the cited abstract reports peak concentration, exposure, half-life, volume and clearance, and no peak time. It is DISCLOSED RATHER THAN DELETED: a midpoint of a narrow range is usually inside the true spread, and removing it would fall back on the solver default of 1.0 per hour, which is worse for most of these records.
Pharmacokinetics
- Oral — t½ 8 h · F 72% · ka 1.25 h⁻¹ · Vd 420 L
Sources: PMID:10671903, PMID:18520604